Decker Kathleen M, Lambert Pascal, Feely Allison, Bucher Oliver, Kim Julian O, Hebbard Pamela, Thiessen Maclean, Fatoye Tunji, Pitz Marshall, Koul Rashmi, Czaykowski Piotr
CancerCare Manitoba Research Institute, CancerCare Manitoba, 675 McDermot Avenue, Winnipeg, MB R3E 0V9, Canada.
Department of Community Health Sciences, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, 750 Bannatyne Avenue, Winnipeg, MB R3E 0V9, Canada.
Curr Oncol. 2021 Aug 12;28(4):3081-3090. doi: 10.3390/curroncol28040269.
Individuals with cancer are vulnerable to infection with SARS-CoV-2, the virus causing COVID-19. Physical distancing, the reallocation of health care resources, and the implementation of procedures to reduce the spread of COVID-19 may also have serious consequences for people with cancer. We evaluated the impact of COVID-19 on new cancer diagnoses and oncology care in Manitoba, Canada using an interrupted time series design and data from the Manitoba Cancer Registry and CancerCare Manitoba's (CCMB) electronic medical record. In April 2020, there was a 23% decrease in new cancer diagnoses, a 21% decrease in pathology reports, and a 43% reduction in surgical resections. There was no difference in new cancer diagnoses by August 2020, surgery by July 2020, and pathology reports by September 2020. From April 2020 to June 2021, there was a 13% decrease in radiotherapy (RT) fractions, an 18% decrease in UCC visits, and a 52% decrease in in-person visits. There was no change in intravenous chemotherapy visits per month, first RT visits, or overall patient visits. The impact of COVID-19 on shifts in the stage at diagnosis and survival will be assessed in future analyses.
癌症患者易感染导致COVID-19的SARS-CoV-2病毒。保持社交距离、重新分配医疗资源以及实施减少COVID-19传播的程序，对癌症患者也可能产生严重后果。我们采用中断时间序列设计，并利用加拿大曼尼托巴省癌症登记处和曼尼托巴癌症护理中心（CCMB）的电子病历数据，评估了COVID-19对加拿大曼尼托巴省新癌症诊断和肿瘤护理的影响。2020年4月，新癌症诊断数量下降了23%，病理报告数量下降了21%，手术切除数量减少了43%。到2020年8月，新癌症诊断数量、到2020年7月的手术数量以及到2020年9月的病理报告数量均无差异。从2020年4月到2021年6月，放疗（RT）次数下降了13%，门诊化疗诊所就诊次数下降了18%，面对面就诊次数下降了52%。每月静脉化疗就诊次数、首次放疗就诊次数或总体患者就诊次数均无变化。COVID-19对诊断分期和生存变化的影响将在未来分析中评估。
